(AOF) – Sanofi announced on Friday that the European Commission has approved Beyfortus treatment, developed with AstraZaneca and also known as nirsevimab, for the prevention of respiratory syncytial virus (RSV) infections in children. Beyfortus is therefore the first and only single-dose passive immunizing agent indicated for all children. Respiratory syncytial virus (RSV) infects almost all children before the age of two.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of AOF’s real-time stock market information service, and its associates. Consequently, any reproduction, copying, duplication, modification, transfer, redistribution, translation, commercial exploitation or otherwise, creation of a hyperlink or re-use in any way of this information is subject to the prior written consent of OPTION. contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it deems safest. However, without prejudice to its gross negligence, OPTION FINANCES SAS and its contributors do not guarantee in any way the absence of errors and defects, even hidden, nor the completeness or lack of conformity to any use of such data and OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must indemnify OPTION FINANCE SAS and its contributors from any claims deriving from such use.
Get our latest news
Every morning, the information to remember on the financial markets.
